Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, Trieselmann K, Copeland VC, Zhang S, Black G, McDonnell S, Gregory J, Johnson R, Moore R, Jones RL, Cranmer LD. Pollack SM, et al. Among authors: cranmer ld. JAMA Oncol. 2020 Nov 1;6(11):1778-1782. doi: 10.1001/jamaoncol.2020.3689. JAMA Oncol. 2020. PMID: 32910151 Free PMC article. Clinical Trial.
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. Chawla SP, et al. Among authors: cranmer ld. J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi: 10.1200/JCO.2013.54.3660. Epub 2014 Sep 2. J Clin Oncol. 2014. PMID: 25185097 Free PMC article. Clinical Trial.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Ribas A, et al. Among authors: cranmer ld. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115796 Free PMC article. Clinical Trial.
Targeting gastrointestinal stromal tumors: the role of regorafenib.
Schroeder B, Li Z, Cranmer LD, Jones RL, Pollack SM. Schroeder B, et al. Among authors: cranmer ld. Onco Targets Ther. 2016 May 20;9:3009-16. doi: 10.2147/OTT.S104081. eCollection 2016. Onco Targets Ther. 2016. PMID: 27284251 Free PMC article. Review.
Pazopanib in the management of advanced soft tissue sarcomas.
Cranmer LD, Loggers ET, Pollack SM. Cranmer LD, et al. Ther Clin Risk Manag. 2016 Jun 9;12:941-55. doi: 10.2147/TCRM.S84792. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27354810 Free PMC article. Review.
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL. Pollack SM, et al. Among authors: cranmer ld. Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2. Cancer. 2017. PMID: 28463396 Free PMC article.
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Tap WD, et al. Among authors: cranmer ld. Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Lancet Oncol. 2017. PMID: 28651927 Free PMC article. Clinical Trial.
Propranolol for the treatment of vascular sarcomas.
Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Wagner MJ, et al. Among authors: cranmer ld. J Exp Pharmacol. 2018 Sep 6;10:51-58. doi: 10.2147/JEP.S146211. eCollection 2018. J Exp Pharmacol. 2018. PMID: 30233257 Free PMC article. Review.
Response to PD1 inhibition in conventional chondrosarcoma.
Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD. Wagner MJ, et al. Among authors: cranmer ld. J Immunother Cancer. 2018 Sep 25;6(1):94. doi: 10.1186/s40425-018-0413-z. J Immunother Cancer. 2018. PMID: 30253794 Free PMC article.
96 results